RESUMEN
Determination of antibodies against ToRCH antigens at the beginning of pregnancy allows assessment of both the maternal immune status and the risks to an adverse pregnancy outcome. Age-standardised seroprevalences were determined in sera from 1009 women of childbearing age residing in Mexico, Brazil, Germany, Poland, Turkey or China using a multiparametric immunoblot containing antigen substrates for antibodies against Toxoplasma gondii, rubella virus, cytomegalovirus (CMV), herpes simplex viruses (HSV-1, HSV-2), Bordetella pertussis, Chlamydia trachomatis, parvovirus B19, Treponema pallidum and varicella zoster virus (VZV). Seroprevalences for antibodies against HSV-1 were >90% in samples from Brazil and Turkey, whereas the other four countries showed lower mean age-adjusted seroprevalences (range: 62.5-87.9%). Samples from Brazilian women showed elevated seroprevalences of antibodies against HSV-2 (40.1%), C. trachomatis (46.8%) and B. pertussis (56.6%) compared to the other five countries. Seroprevalences of anti-T. gondii antibodies (0.5%) and anti-parvovirus B19 antibodies (7.5%) were low in samples from Chinese women, compared to the other five countries. Samples from German women revealed a low age-standardised seroprevalence of anti-CMV antibodies (28.8%) compared to the other five countries. These global differences in immune status of women in childbearing age advocate country-specific prophylaxis strategies to avoid infection with ToRCH pathogens.
Asunto(s)
Anticuerpos Antibacterianos/sangre , Anticuerpos Antiprotozoarios/sangre , Anticuerpos Antivirales/sangre , Infecciones Bacterianas/epidemiología , Salud Global , Estudios Seroepidemiológicos , Adulto , Infecciones Bacterianas/sangre , Infecciones Bacterianas/transmisión , Femenino , Humanos , Transmisión Vertical de Enfermedad Infecciosa , Persona de Mediana Edad , Embarazo , Infecciones por Protozoos/sangre , Infecciones por Protozoos/epidemiología , Infecciones por Protozoos/transmisión , Virosis/sangre , Virosis/epidemiología , Virosis/transmisión , Adulto JovenRESUMEN
PURPOSE: The standard treatment for patients with stage III non-small cell lung cancer (NSCLC), unsuitable for resection and with good performance, is definitive radiotherapy with cisplatin-based chemotherapy. Our aim is to evaluate the effect of the maximum value of standardized uptake values (SUVmax) of the primary tumor in positron emission tomography-computed tomography (PET/CT) before treatment on complete response (CR) and overall survival. METHODS: The data of 73 stage III NSCLC patients treated with concurrent definitive chemoradiotherapy (CRT) between 2008 and 2017 and had PET/CT staging in the pretreatment period were evaluated. ROC curve analysis was performed to determine the ideal cut-off value of pretreatment SUVmax to predict CR. RESULTS: Median age was 58 years (range 27-83 years) and 66 patients were male (90.4%). Median follow-up time was 18 months (range 3-98 months); median survival was 23 months. 1-year overall survival (OS) rate and 5-year OS rate were 72 and 19%, respectively. Median progression-free survival (PFS) was 9 months; 1-year PFS rate and 5-year PFS rate were 38 and 19%, respectively. The ideal cut-off value of pretreatment SUVmax that predicted the complete response of CRT was 12 in the ROC analysis [AUC 0.699 (0.550-0.833)/P < 0.01] with a sensitivity of 83%, and specificity of 55%. In patients with SUVmax < 12, CR rate was 60%, while, in patients with SUV ≥ 12, it was only 19% (P = 0.002). Median OS was 26 months in patients with pretreatment SUVmax < 12, and 21 months in patients with SUVmax ≥ 12 (HR = 2.93; 95% CI 17.24-28.75; P = 0.087). CR rate of the whole patient population was 26%, and it was the only factor that showed a significant benefit on survival in both univariate and multivariate analyses. CONCLUSION: Pretreatment SUVmax of the primary tumor in PET/CT may predict CR in stage III NSCLC patients who were treated with definitive CRT. Having clinical CR is the only positive predictive factor for prolonged survival.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/radioterapia , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Carcinoma de Pulmón de Células no Pequeñas/patología , Quimioradioterapia , Femenino , Fluorodesoxiglucosa F18/farmacocinética , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Tomografía Computarizada por Tomografía de Emisión de Positrones , Pronóstico , Curva ROC , Radiofármacos/farmacocinética , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
A total of 32 Wistar rats were divided into four equal groups: (I) sham, (II) ischemia, (III) reperfusion and (IV) Potentilla fulgens. In groups I and II, ovary torsion was not performed and no drug was administered. In group III, 1 h of ischemia and 2 h of reperfusion were performed and no drug was given. Group IV received 400 mg/kg/day Potentilla fulgens intraperitoneally 5 days before Ischemia-reperfusion. All the parameters were observed to be significantly decreased (P<0.05) in all the experimental groups compared to the control group. In the sections of the ischemia-reperfusion group, degeneration of epithelium, dilation of blood vessels were observed. Potentilla fulgens administration reduced the morphological changes by induced I/R; in particular, infiltration, hemorrhage and vascular dilatation were decreased. Potentilla fulgens application during torsion, it plays an important role in maintaining the epithelial structure with E-cadherin expression. We suggest that PECAM-1(CD31) are a regulator of the microvascular response of the tubal mucosa.
Un total de 32 ratas Wistar fueron divididas en cuatro grupos: (I) Sham, (II) isquemia, (III) reperfusión y (IV) Potentilla fulgens. En los grupos I y II, no se realizó la torsión de ovario y ni se administró ningún tipo de fármaco. En el grupo III, se produjo isquemia por 1 h seguido de reperfusión por 2 h (I/R), sin administracion de fármacos. El grupo IV recibió 400 mg/kg por día de Potentilla fulgens vía intraperitoneal durante cinco días previo al protocolo de isquemia-reperfusión. Se observó que todos los parámetros disminuyeron significativamente (P <0,05) en todos los grupos experimentales en comparación con el grupo control. En las secciones del grupo de isquemia-reperfusión, se observó degeneración del epitelio y dilatación de los vasos sanguíneos. La administración de Potentilla fulgens reduce los cambios morfológicos inducidos por I/R; en particular, la infiltración, la hemorragia y la dilatación vascular. La aplicación de Potentilla fulgens durante la torsión, desempeña un papel importante en el mantenimiento de la estructura epitelial con la expresión de E-cadherina. Sugerimos que PECAM-1 (CD31) es un regulador de la respuesta microvascular de la mucosa tubárica.